Mutations of the parkin gene, compositions, methods and uses

Abstract

The invention concerns nucleic acids coding for mutated or truncated forms of the human parkin gene, or forms comprising multiplication of exons, and the corresponding proteins and antibodies. The invention also concerns methods and kits for identifying mutations of the parkin gene, and for studying compounds for therapeutic purposes.

1 - 40 . (canceled) 
     
     
         41 . An oligonucleotide comprising a fragment, or the complementary sequence thereof, of a parkin gene that comprises a genetic alteration selected from the group consisting of:
 a) a deletion of one or more exons selected from the group consisting of: exon 2, exons 2-3, exons 2-4, exons 3-4, exons 3-6, exons 3-9, exon 5, exons 5-6, exon 6, exons 6-7, exons 7-9, and exon 8;   b) a multiplication of exons selected from the group consisting of: a triplication of exon 2, a duplication of exon 3, a duplication of exon 6, a duplication of exon 7, and a duplication of exon 11;   c) a point mutation selected from the group consisting of: a mutation from adenine to thymine at a position corresponding to position 584 of SEQ ID NO: 1, a mutation from guanine to adenine at a position corresponding to position 601 of SEQ ID NO: 1, a mutation from adenine to thymine at a position corresponding to position 734 of SEQ ID NO: 1, a mutation from cytosine to thymine at a position corresponding to position 867 of SEQ ID NO:1, a mutation from thymine to adenine at a position corresponding to position 905 of SEQ ID NO: 1, a mutation from cytosine to thymine at a position corresponding to position 924 of SEQ ID NO: 1, a mutation from guanine to adenine at a position corresponding to position 939 of SEQ ID NO: 1, a mutation from thymine to guanine at a position corresponding to position 966 of SEQ ID NO: 1, a mutation from guanine to adenine at a position corresponding to position 1084 of SEQ ID NO: 1, a mutation from cytosine to thymine at a position corresponding to position 1101 of SEQ ID NO:1, a mutation from guanine to cytosine at a position corresponding to position 1239 of SEQ ID NO:1, a mutation from guanine to adenine at a position corresponding to position 1281 of SEQ ID NO: 1, a mutation from cytosine to adenine at a position corresponding to position 1345 of SEQ ID NO: 1, a mutation from guanine to adenine at a position corresponding to position 1390 of SEQ ID NO: 1, and a mutation from guanine to adenine at a position corresponding to position 1459 of SEQ ID NO:1;   d) a deletion of 1 or more contiguous base pairs selected from the group consisting of: a deletion of nucleotides adenine and guanine at positions corresponding to positions 202-203 of SEQ ID NO:1, a deletion of adenine at a position corresponding to position 255 of SEQ ID NO: 1, and a deletion of nucleotides guanine and adenine at positions corresponding to positions 1142-1143 of SEQ ID NO:1; and   e) an insertion of 1 or more contiguous base pairs selected from the group consisting of: an insertion of guanine and thymine at positions corresponding to 321-322 of SEQ ID NO:1;   wherein the oligonucleotide is detectably labeled.   
     
     
         42 . The oligonucleotide of  claim 41 , wherein the detectable label is selected from the group consisting of a radioactive label, a fluorescent label, an enzymatic label, a chemical label. 
     
     
         43 . The oligonucleotide of  claim 41 , wherein the oligonucleotide has less than 500 bp. 
     
     
         44 . The oligonucleotide of  claim 41 , wherein the oligonucleotide has less than 300 bp. 
     
     
         45 . The oligonucleotide of  claim 41 , wherein the oligonucleotide has about 5 to about 100 bp. 
     
     
         46 . The oligonucleotide of  claim 41 , wherein the oligonucleotide has about 5 to about 50 bp. 
     
     
         47 . The oligonucleotide of  claim 41 , wherein the oligonucleotide specifically hybridizes to the parkin gene comprises a genetic alteration under stringent conditions, and does not hybridize to the wild type parkin gene under stringent conditions. 
     
     
         48 . The oligonucleotide of  claim 41 , wherein the genetic alteration comprises a point mutation that results in a nonsense mutation. 
     
     
         49 . The oligonucleotide of  claim 48 , wherein the nonsense mutation affects exon 7, exon 12, or a combination thereof. 
     
     
         50 . The oligonucleotide of  claim 48 , wherein the point mutation comprises the point mutation 905T>A that introduces a stop codon at a position corresponding to the Cys268 residue encoded by the sequence of SEQ ID NO: 1, or the point mutation 1459G>A that introduces a stop codon at a position corresponding to the Trp453 residue encoded by the sequence of SEQ ID NO: 1. 
     
     
         51 . The oligonucleotide of  claim 41 , wherein the genetic alteration is a point mutation that results in a missense mutation. 
     
     
         52 . The oligonucleotide of  claim 51 , wherein the missense mutation causes a nonconservative change in the amino acid sequence encoded by the sequence of SEQ ID NO: 1. 
     
     
         53 . The oligonucleotide of  claim 51 , wherein the missense mutation comprises a point mutation selected from the group consisting of 584A>T at a position corresponding to SEQ ID NO: 1 (Lys161Asn), 601G>A T at a position corresponding to SEQ ID NO:1 (Ser167Asn), 734A>T at a position corresponding to SEQ ID NO:1 (Lys211Asn), 867C>T T at a position corresponding to SEQ ID NO: 1 (Arg256Cys), 924C>T at a position corresponding to SEQ ID NO: 1 (Arg275Trp), 939G>A at a position corresponding to SEQ ID NO: 1 (Asp280Asn), 966T>G (Cys289Gly), 1084G>A at a position corresponding to SEQ ID NO: 1 (Gly328Glu), 1101C>T at a position corresponding to SEQ ID NO: 1 (Arg334Cys), 1281G>A T at a position corresponding to SEQ ID NO:1 (Asp394Asn), and 1390G>A T at a position corresponding to SEQ ID NO:1 (Gly430Asp). 
     
     
         54 . The oligonucleotide of  claim 51 , wherein the missense mutation causes a conservative change in the amino acid sequence encoded by the sequence of SEQ ID NO: 1. 
     
     
         55 . The oligonucleotide of  claim 54 , wherein the missense mutation comprises a point mutation selected from the group consisting of 1239G>C T at a position corresponding to SEQ ID NO: 1 (Val380Leu) and 1345C>A T at a position corresponding to SEQ ID NO:1 (Thr415Asn). 
     
     
         56 . The oligonucleotide of  claim 54 , wherein the missense mutation affects a potential phosphorylation site of a polypeptide encoded by said isolated nucleic acid molecule. 
     
     
         57 . The oligonucleotide of  claim 56 , wherein the point mutation is Thr415Asn. 
     
     
         58 . The oligonucleotide of  claim 41 , wherein the genetic alteration comprises a deletion of one or more contiguous base pair(s) that causes a reading frame shift. 
     
     
         59 . The oligonucleotide of  claim 58 , wherein the deletion is selected from the group consisting of: a deletion of the nucleotides adenine and guanine at positions corresponding to positions 202-203 of SEQ ID NO: 1, a deletion of the nucleotide adenine at a position corresponding to position 255 of SEQ ID NO:1, and a deletion of the nucleotides guanine and adenine at positions corresponding to positions 1142-1143 of SEQ ID NO:1. 
     
     
         60 . The oligonucleotide of  claim 58 , wherein the genetic alteration comprises an insertion of one or more contiguous base pair(s) that causes a reading frame shift. 
     
     
         61 . The oligonucleotide of  claim 60 , wherein the insertion is an insertion of nucleotides guanine and thymine at positions corresponding to positions 321-322 of SEQ ID NO:1. 
     
     
         62 . A kit for detection of a genetic alteration of a parkin gene, comprising at least one of the oligonucleotides of  claim 41 .